The effect and safety of mizoribine for IgA Nephropathy in children

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-10001124

Enrollment

Unknown

Registered

2010-12-04

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

1:mizoribine 3~5mg/kg.d

Eligibility

Sex/Gender

All

Age

5 Years to 16 Years

Inclusion criteria

Inclusion criteria: IgAN in children

Exclusion criteria

Exclusion criteria: 1. patients with renal dysfunction (creatinine clearance rate 140umol/L (1.5mg/dL); 2. long-term use of cyclosporine; 3. patients who are allergic to mizoribine seriously; 4. the white blood cell count <3,000/mm3; 5. serious complications of liver, kidney or blood system.

Design outcomes

Primary

Measure	Time frame
humoral immune indices;blood routine test;urinary routine test;liver and kidney function;	—

Secondary

Measure	Time frame
urinary NAG enzyme;urinary C3;alpha 2-M;renal pathology;urinary RBP;urinary sedimentation;ESR;	—

Countries

China

Contacts

Public ContactZhengkun Xia

njxzk@126.com+86 025-80861386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026